BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, November 13, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» Dewpoint Therapeutics nominates condensate modulator as development candidate for Wnt-driven cancers
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Dewpoint Therapeutics nominates condensate modulator as development candidate for Wnt-driven cancers
Oct. 29, 2024
No Comments
Dewpoint Therapeutics Inc. has nominated its first development candidate, DPTX-3186, an orally administered small-molecule condensate modulator inhibiting the oncogenic function of β-catenin, for the treatment of Wnt-driven cancers.
BioWorld Science
Cancer
